Group psychedelic therapy: empirical estimates of cost-savings and improved access.

ABSTRACT:

Objective

To compare group and individual psychedelic-assisted therapy in terms of clinician time, costs and patient access.

Methods

Using 2023 data from two group therapy trial sites, one using 3,4-Methylenedioxymethamphetamine (MDMA) to treat posttraumatic stress disorder (PTSD), and one using psilocybin to treat major depressive disorder (MDD), we compared overall variable costs, clinician costs and clinician time required by therapy protocols utilizing groups versus individual patient therapy. Using published literature, we estimated the prevalence of adults with PTSD and MDD eligible for treatment with psychedelic therapy and projected the savings in time and cost required to treat these prevalent cases.

Results

Group therapy saved 50.9% of clinician costs for MD

SUBMITTER: Marseille E 

PROVIDER: S-EPMC10731307 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature